Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1915 of 6351
-
Radiation after CAR-T: a new hope for myeloma patients?
Disease control Recruiting nowThis study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA CAR-T cell therapy with active …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Recruiting nowEvaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Phase 1/2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis is a phase II, open label, multicenter study of AZD4205 administered orally in participants with r/r PTCL to determine its safety, tolerability, PK, and anti-tumor activity. Eligible participants are those who had pathologically confirmed PTCL and have relapsed after or been…
Phase 2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a mitochondrial booster calm ulcerative colitis without heavy immune drugs?
Disease control OngoingThis is a Phase 2b, multi-centered, randomized, placebo-controlled trial with treatment phase over 24 weeks. Ulcerative Colitis (UC) is a condition that causes inflammation and ulceration of the inner lining of the rectum and colon (the large bowel). In UC, ulcers develop on the…
Phase 2 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug TAKHZYRO tracked for Long-Term safety in rare swelling disorder
Disease control OngoingThis study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main a…
Sponsor: Takeda • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could argon gas help comatose cardiac arrest patients?
Disease control Recruiting nowPreclinical studies suggest that argon (Ar) might diminish the neurological and myocardial damage after any hypoxic-ischemic insult. Indeed, Ar has been tested in different models of ischemic insult, at concentrations ranging from 20% up to 80%. Overall, Ar emerged as a protectiv…
Phase 2 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 26, 2026 18:00 UTC
-
Could a single IV antibiotic dose send kids home sooner?
Disease control Recruiting nowUrinary tract infections (UTI) are commonly encountered in children, with 7% diagnosed with at least one UTI by the age of 19 years. The evidence for treatment of uncomplicated UTI is clear; oral antibiotics are as good as intravenous (IV) antibiotics, usually for a total of 7 da…
Phase 4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can stem cells heal the brain after a stroke? new trial aims to find out
Disease control OngoingThe purpose of this study was to determine the effectiveness of a combination of intranasal conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in acute stroke patients to induce neurogenesis.
Phase 1/2 • Sponsor: PT. Prodia Stem Cell Indonesia • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThe primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab. The primary objective of Parts B and C is to evaluate the an…
Phase 1/2 • Sponsor: Shionogi • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug SHR-A1904 tested in patients with advanced cancers
Disease control Recruiting nowThe study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, …
Phase 1/2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Why does low back pain keep coming back? a study hunts for the warning signs.
Knowledge-focused CompletedLow back pain (LBP) is the leading cause of disability and one of the most common reasons for physician visits in primary care, with a 33 % rate of recurrence during the first year, converting LBP into a chronic condition. The french High healthy authority recommend early occupa…
Sponsor: Fondation Ildys • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Brain training shows promise for suicidal teens
Symptom relief CompletedA non invasive treatment study including participants at risk for suicide attempts and undergoing neurofeedback training. Neurofeedback is controlling your brain activity in real time inside the scanner.
Phase 1 • Sponsor: University of Minnesota • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy aims to outsmart advanced liver cancer
Disease control Recruiting nowThis phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to n…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Bladder cancer breakthrough? trial tests stopping immunotherapy early
Disease control OngoingThis phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors. Immunotherapy with monoclonal antibodies, such as a…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could a gel patch fix a hole in your ear drum?
Disease control CompletedThis study is a double blinded, placebo-controlled phase II study evaluating the efficacy of FGF-2 for the treatment of chronic non-healing tympanic membrane perforations (TMP). The documentation of TM closure will be the main efficacy outcome measure. Pretreatment photographs wi…
Phase 2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Targeted drug shows promise for rare bone cancer
Disease control OngoingThis is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disea…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a smaller booster dose still protect against COVID-19?
Vaccine CompletedThis clinical trial is a single-blind, randomised study to determine the reactogenicity and immunogenicity of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) vaccine (Pfizer-BioNTech) as booster dose in adults, who have previously received either Sinopharm (BBIBP-Cor…
Phase 3 • Sponsor: Murdoch Childrens Research Institute • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
New drug-radiation combo targets deadly brain cancer
Disease control OngoingThis is an open-label, single-center Phase 0/1b study that will enroll at least 27 participants with recurrent WHO Grade 4 Glioma requiring re-radiation and approximately 35 participants with newly-diagnosed WHO Grade 4 glioma (nGBM). The trial will be composed of a Phase 0 compo…
Early phase 1 • Sponsor: Nader Sanai • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Heart surgery upgrade: zap away bad rhythms while implanting pump
Disease control Recruiting nowTo investigate the effect of VTA ablation at the time of LVAD implant to see if it can reduce the incidence of VTA after surgery
Phase 4 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Double punch for prostate cancer: electric pulses plus radiation
Disease control OngoingThis is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform…
Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC